International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(23), С. 12990 - 12990

Опубликована: Дек. 3, 2024

Head and neck cancer (HNC) represents a challenging oncological entity with significant morbidity mortality rates. Despite advances in conventional therapies, including surgery, chemotherapy, radiation therapy, the overall survival rates for advanced HNC remain suboptimal. In recent years, emerging field of oncolytic virotherapy has gained attention as promising therapeutic approach various malignancies, HNC. This review provides comprehensive overview current understanding viruses (Ovs) context treatment, their mechanisms action, preclinical clinical studies, challenges, future directions. Future focuses on improving delivery specificity through nanoparticle carriers genetic modifications to enhance tumor targeting immune response. Combining different OVs integrating them immunotherapies, such checkpoint inhibitors, could overcome resistance improve outcomes. Personalized approaches rigorous trials are key ensuring safety effectiveness treating

Язык: Английский